Canakinumab, a human monoclonal antibody against IL-1β, has been established for over a decade in the treatment of rheumatological conditions and other immunological diseases and recently has been shown to be efficacious in reducing lung cancer incidence in a dose-dependent manner (58). This evidence concerns the gene IL1B and lung carcinoma.